A Danish ICD-study in Patients with Coronary Artery Disease Resuscitated from Ventricular Fibrillation
Launched by RIGSHOSPITALET, DENMARK · Sep 29, 2020
Trial Information
Current as of May 03, 2025
Recruiting
Keywords
ClinConnect Summary
The Danish ICD study, known as DanICD, is looking at whether implanting a device called an Implantable Cardioverter Defibrillator (ICD) can help patients who have coronary artery disease and have survived a life-threatening heart event called ventricular fibrillation. This study is for patients who have had a cardiac arrest, received treatment to restore blood flow to their heart, and have a heart function score (called LVEF) of more than 35%. The goal is to see if the ICD can help prevent future cardiac arrests in these patients.
To be eligible for this study, participants must be at least 18 years old and have experienced a cardiac arrest due to a specific type of abnormal heart rhythm. They must also have undergone a procedure to improve blood flow to their heart. However, individuals with certain types of heart problems, those who have had recent heart surgery, or those with serious health conditions may not qualify. If you choose to participate, you will be closely monitored to assess the effects of the ICD and your overall health following the procedure. This study aims to improve care for patients like you and potentially save lives.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients with CAD and cardiac arrest due to VF/VT, where angiogram is performed with complete revascularization (PCI, CABG or hybrid coronary revascularization) before ICD implantation. Unfavorable artery for PCI (i.e., excessive vessel tortuosity or chronic total occlusion) or high-risk invasive treatment is not mandatory in order to achive complete revascularization.
- • Age ≥18 years
- • LVEF \>35% at the time of discharge. The most recent LVEF assessment on which the current medical treatment will be based at the time of entry into the study will be used as baseline LVEF.
- Exclusion Criteria:
- • Non-ischemic cause of cardiac arrest (i.e. ion channel diseases, non-ischemic cardiomyopathy)
- • Previous CABG within the last 3 months before index hospitalization
- • Life expectancy less than 1 year or severe neurologic outcome
- • Unable or unwilling to give informed consent
- • Pregnancy
About Rigshospitalet, Denmark
Rigshospitalet, located in Copenhagen, Denmark, is one of the leading hospitals in Scandinavia and a prominent center for clinical research and innovation. As a key academic institution affiliated with the University of Copenhagen, Rigshospitalet is dedicated to advancing healthcare through rigorous clinical trials and groundbreaking research across various medical disciplines. The hospital’s commitment to excellence is reflected in its multidisciplinary approach, collaboration with international research networks, and focus on improving patient outcomes through evidence-based practices. With state-of-the-art facilities and a team of highly qualified professionals, Rigshospitalet plays a crucial role in translating scientific discoveries into effective treatments and therapies.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Copenhagen, , Denmark
Patients applied
Trial Officials
Reza Jabbari, MD, PhD
Principal Investigator
Rigshospitalet, Denmark
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials